PriceTargets.com logo

OptimizeRx - OPRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.60
  • Forecasted Upside: 67.02%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$9.34 As of 11/28/2023 05:29 PM ET
▼ -0.13 (-1.37%)

This chart shows the closing price for OPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OptimizeRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPRX

Analyst Price Target is $15.60
▲ +67.02% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for OptimizeRx in the last 3 months. The average price target is $15.60, with a high forecast of $20.00 and a low forecast of $13.00. The average price target represents a 67.02% upside from the last price of $9.34.

This chart shows the closing price for OPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in OptimizeRx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2023Roth MkmLower TargetBuy ➝ Buy$31.00 ➝ $20.00Low
8/15/2023Lake Street CapitalLower TargetBuy ➝ Buy$18.00 ➝ $13.00Low
8/15/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$18.00 ➝ $14.00Low
8/15/2023B. RileyLower TargetBuy ➝ Buy$28.00 ➝ $18.00Low
8/15/2023Stifel NicolausLower TargetBuy ➝ Buy$16.00 ➝ $13.00Low
3/21/2023William BlairReiterated RatingOutperformLow
3/9/2023Roth CapitalReiterated RatingBuyLow
3/9/2023Lake Street CapitalLower Target$25.00 ➝ $18.00Low
3/9/2023B. RileyLower Target$30.00 ➝ $28.00Low
3/9/2023Stifel NicolausLower Target$19.00 ➝ $16.00Low
3/9/2023Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $18.00Low
2/2/2023B. RileyReiterated RatingBuy$30.00Low
1/27/2023SVB LeerinkReiterated RatingOutperformLow
10/31/2022Stifel NicolausInitiated CoverageBuy$19.00Low
8/10/2022SVB LeerinkLower TargetOutperform$38.00 ➝ $30.00Low
8/10/2022Piper SandlerLower TargetNeutral$29.00 ➝ $16.00Low
7/20/2022B. RileyLower TargetBuy$71.00 ➝ $56.00Low
7/15/2022SVB LeerinkInitiated CoverageOutperform$38.00Low
7/1/2022Piper SandlerInitiated CoverageNeutral$29.00Low
5/5/2022Royal Bank of CanadaLower Target$100.00 ➝ $50.00High
5/5/2022Roth CapitalLower Target$112.00 ➝ $66.00High
2/16/2022Lake Street CapitalLower TargetBuy$98.00 ➝ $76.00Medium
11/10/2021Roth CapitalBoost TargetBuy$85.00 ➝ $112.00Low
11/10/2021Royal Bank of CanadaBoost TargetOutperform$67.00 ➝ $100.00Medium
11/9/2021William BlairReiterated RatingOutperformHigh
10/18/2021B. RileyReiterated RatingBuy$102.00High
8/5/2021B. RileyBoost TargetBuy$80.00 ➝ $95.00High
5/7/2021B. RileyBoost TargetBuy$75.00 ➝ $80.00High
4/12/2021Royal Bank of CanadaInitiated CoverageOutperform$65.00Low
2/25/2021B. RileyBoost TargetBuy$60.00 ➝ $75.00High
2/25/2021Roth CapitalBoost TargetTop Pick ➝ Buy$70.00 ➝ $85.00High
1/26/2021Lake Street CapitalBoost TargetBuy$40.00 ➝ $54.00High
1/7/2021Lake Street CapitalBoost Target$26.00 ➝ $40.00N/A
1/7/2021Roth CapitalBoost TargetTop Pick ➝ Buy$40.00 ➝ $70.00N/A
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$34.00 ➝ $50.00N/A
11/10/2020Lake Street CapitalBoost TargetBuy$21.00 ➝ $26.00Medium
11/10/2020B. RileyBoost TargetBuy$30.00 ➝ $34.00Medium
9/14/2020Roth CapitalBoost TargetBuy$30.00 ➝ $40.00High
8/6/2020B. RileyBoost Target$22.00 ➝ $28.00Low
8/6/2020Lake Street CapitalBoost TargetBuy$17.00 ➝ $20.00High
6/8/2020Lake Street CapitalBoost TargetReduce ➝ Buy$14.00 ➝ $17.00Medium
5/5/2020B. RileyBoost TargetBuy$18.00 ➝ $22.00High
4/7/2020B. RileyLower TargetBuy$20.00 ➝ $18.00Medium
1/3/2020William BlairInitiated CoverageOutperformLow
12/30/2019B. RileyLower TargetBuy$21.00 ➝ $20.00High
1/3/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
(Data available from 11/28/2018 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2023
  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/30/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

OptimizeRx logo
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.
Read More

Today's Range

Now: $9.34
Low: $9.28
High: $9.52

50 Day Range

MA: $8.39
Low: $7.06
High: $10.02

52 Week Range

Now: $9.34
Low: $6.92
High: $21.27

Volume

117,361 shs

Average Volume

177,658 shs

Market Capitalization

$169.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of OptimizeRx?

The following sell-side analysts have issued research reports on OptimizeRx in the last twelve months: B. Riley, Lake Street Capital, Roth Capital, Roth Mkm, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for OPRX.

What is the current price target for OptimizeRx?

5 Wall Street analysts have set twelve-month price targets for OptimizeRx in the last year. Their average twelve-month price target is $15.60, suggesting a possible upside of 67.0%. Roth Mkm has the highest price target set, predicting OPRX will reach $20.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $13.00 for OptimizeRx in the next year.
View the latest price targets for OPRX.

What is the current consensus analyst rating for OptimizeRx?

OptimizeRx currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPRX will outperform the market and that investors should add to their positions of OptimizeRx.
View the latest ratings for OPRX.

What other companies compete with OptimizeRx?

Other companies that are similar to OptimizeRx include Edgio, ZeroFox, Rimini Street, Uxin and Gravity. Learn More about companies similar to OptimizeRx.

How do I contact OptimizeRx's investor relations team?

OptimizeRx's physical mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company's listed phone number is (248) 651-6568 and its investor relations email address is [email protected]. The official website for OptimizeRx is www.optimizerx.com. Learn More about contacing OptimizeRx investor relations.